Client Results
What changes when data becomes strategy.
Every engagement is different because every person's biology is different. What these outcomes share is a pattern: structured interpretation reveals what fragmented data obscures.
Across All Engagements
0.5%
Average HbA1c
reduction
58%
Average supplement
stack reduction
90
Days to measurable
biomarker change
100%
Clients with at least one
key marker improved
The case studies below represent real engagement outcomes with identifying details changed. Biomarker values and timelines are reported as they occurred. Results vary between individuals. These outcomes demonstrate the quality of analysis your guests receive through a property partnership.
Axiom Longevity does not provide medical advice, diagnosis, or treatment. All interventions are strategic and educational.
Case Study 01
The Optimizer Without a Framework
Guest profile: Executive, 47
What He Arrived With
Fourteen supplements taken daily. Two wearable devices. A CGM he had worn for three months. Annual blood work from a concierge physician showing "everything normal." Despite all of this, he described feeling like he was guessing. He had no way to determine which interventions were producing results and which were redundant.
What Axiom Found
His comprehensive panel revealed HbA1c at 5.7 percent, trending upward over three years despite an aggressive exercise routine. His concierge physician had noted it was "within range." Genetic analysis revealed MTHFR C677T heterozygous and APOE3/4 variants that reframed his entire risk profile. His supplement stack included three products competing for the same absorption pathways, and two that were actively redundant.
HbA1c
5.7 → 5.2
60 days
Supplements
14 → 5
64% reduction
ApoB
Monitored
APOE4 protocol active
Outcome
HbA1c returned to optimal range within 60 days through targeted metabolic intervention. Supplement stack reduced by 64 percent with no decline in any tracked biomarker. Cardiovascular monitoring protocol established based on confirmed APOE4 genetic predisposition. His follow up review showed improved metabolic markers across the board, and he reported spending less time managing his health and more time benefiting from it.
Case Study 02
The Invisible Pattern
Guest profile: Founder, 39
What She Arrived With
Three years of annual blood work from her GP, all showing results within reference range. She had been told repeatedly that everything was fine. She came to Axiom not because of a specific symptom but because of a feeling that her resilience had shifted. Recovery from stress took longer. Sleep felt less restorative despite good habits. Energy was inconsistent in ways she could not attribute to any single cause.
What Axiom Found
Her standard panels had never included hsCRP or DHEA sulfate. When tested, hsCRP came back at 2.8 mg/L, indicating moderate systemic inflammation. DHEA S was at the 15th percentile for her age, significantly below optimal. Taken together, these markers told a clear story: chronic stress was eroding her hormonal reserve while driving a low grade inflammatory response. Neither marker would have been caught on a standard panel, and neither was producing obvious symptoms yet.
hsCRP
2.8 → 0.8
71% reduction in 90 days
DHEA S
15th → 45th
Percentile for age
Sleep Score
+18%
Wearable tracked
Outcome
Protocol targeted the stress inflammation loop directly: adrenal support, anti inflammatory nutritional modifications, and a structured stress management framework. hsCRP dropped to 0.8 mg/L within 90 days. DHEA S moved from the 15th to 45th percentile. Sleep architecture improved measurably based on wearable data, and she described a return of the resilience she had noticed fading.
Case Study 03
The Disconnected Data
Guest profile: Investor, 52
What He Arrived With
DNA test completed two years prior through a consumer service. Results were sitting in a portal, unread beyond the ancestry section. Recent blood work from a checkup in Hong Kong showing ApoB at 128 mg/dL, flagged as "borderline" by his physician with a recommendation to "monitor and recheck in six months."
What Axiom Found
Cross referencing his genetic data with his blood work revealed a picture his physician did not have the tools to see. He carried variants associated with reduced LDL receptor efficiency and elevated Lp(a), a genetically determined lipoprotein that significantly amplifies cardiovascular risk when combined with high ApoB. His "borderline" ApoB of 128 mg/dL was not borderline at all in the context of his genetic profile. It was a confirmed, actionable risk that warranted immediate intervention, not six months of monitoring.
ApoB
128 → 74
42% reduction in 90 days
Lp(a)
Identified
Genetic confirmation
Risk Status
Managed
Ongoing protocol active
Outcome
Early intervention strategy established immediately rather than waiting six months. Dietary and supplementation protocol specifically designed for his genetic cardiovascular profile. ApoB reduced to 74 mg/dL within 90 days. Ongoing monitoring protocol established with quarterly ApoB and Lp(a) tracking. His risk was reclassified from "something to watch" to actively managed, potentially years before clinical symptoms would have appeared.
Case Study 04
The Supplement Audit
Guest profile: Creative Director, 44
What She Arrived With
A supplement stack of 19 products accumulated over four years from various practitioner recommendations, podcast suggestions, and personal research. Monthly spend on supplements alone exceeded $400. She had no recent blood work and had never done genetic testing. She described her approach as "doing everything I can" but acknowledged she had no way to measure whether any of it was working.
What Axiom Found
Comprehensive blood work revealed that her vitamin D was already at 72 ng/mL despite taking two separate supplements containing it. Her magnesium levels were optimal, yet she was taking three different magnesium formulations. Several supplements in her stack were competing for absorption, reducing the effectiveness of each. Meanwhile, her fasting insulin was at 11 mIU/L, elevated enough to indicate early insulin resistance, something none of her supplements were addressing.
Supplements
19 → 6
68% reduction
Monthly Cost
$400 → $120
70% cost reduction
Fasting Insulin
11 → 6.2
Normalized in 90 days
Outcome
Supplement stack reduced from 19 to 6 targeted items. Monthly supplement cost dropped from $400 to $120. The six remaining supplements were chosen based on confirmed deficiencies and her specific metabolic profile. Fasting insulin normalized from 11 to 6.2 mIU/L within 90 days through dietary and lifestyle modifications that none of her previous supplements were designed to address. She described the experience as "finally understanding what I actually need instead of guessing."
Case Study 05
The Remote Intelligence
Guest profile: Entrepreneur, 41
What He Arrived With
Existing DNA data from 23andMe, blood work from a premium health screening in Dubai, and a supplement regimen designed by a wellness consultant. He was based too far from Koh Samui to visit and opted for the remote Data Interpretation Report. He sent all his existing data through our secure intake process and booked a strategy session.
What Axiom Found
His existing data was more comprehensive than he realized. Cross referencing his genetic methylation variants with his homocysteine levels (elevated at 14.2 umol/L) revealed a functional methylation impairment that his wellness consultant had not identified. His thyroid panel, which appeared normal on standard reference ranges, showed free T3 at the lower edge of optimal, consistent with the fatigue he had been attributing to travel and jet lag.
Homocysteine
14.2 → 8.6
39% reduction in 60 days
Free T3
Optimized
Targeted support active
Engagement
Remote
Data Interpretation tier
Outcome
Homocysteine reduced from 14.2 to 8.6 umol/L within 60 days through targeted methylated B vitamin supplementation guided by his genetic profile. Thyroid function supported through nutritional and lifestyle interventions. The entire engagement was conducted remotely, using data he already had. No new tests were required for the initial assessment. He described the 48 page report as "the first time anyone connected all my data into a single picture."
Client Perspective
"For the first time, my health data feels like a strategy, not a puzzle. I know exactly what to focus on and why."
Blueprint Client, Southeast Asia
Begin Your Assessment
Your data already contains the answers.
Every engagement begins with your existing biological data. Whether you have a single blood panel or years of accumulated results, the starting point is the same: integration, prioritization, and clarity.